Literature DB >> 1656591

Isolation and enzymatic characterization of protein lambda 2, the reovirus guanylyltransferase.

Z X Mao1, W K Joklik.   

Abstract

Protein lambda 2 of reovirus serotype 3 has been purified to homogeneity from extracts of cells infected with hybrid vaccinia virus strain WR into whose TK gene of the reovirus L2 genome segment under the control of the CPV ATI protein gene promoter had been inserted. Protein lambda 2 is formed in large amounts (final purification factor about 180) as a monomer that shows no tendency to pentamerize into the reovirus core projections/spikes. Isolated protein lambda 2 is reversibly guanylylated by GTP (that is, it carries out the GTP-PPi exchange reaction) and can transfer the -GMP moiety to GTP to form GppppG, to GDP to form GpppG, and to 5'-pp-terminated RNA to form GpppG- caps. These studies confirm previous studies on reovirus cores that indicated that protein lambda 2 is the reovirus guanylyltransferase. Protein lambda 2 possesses neither nucleoside nor RNA triphosphatase activities, nor methyltransferase activities; thus it is the reovirus capping enzyme, but provides neither the required 5'-ppG-terminated substrate nor does it methylate the cap structure. These must be functions of lambda 2 pentamers or of other individual or complexed components of reovirus cores.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656591     DOI: 10.1016/0042-6822(91)90785-a

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  The delta region of outer-capsid protein micro 1 undergoes conformational change and release from reovirus particles during cell entry.

Authors:  Kartik Chandran; John S L Parker; Marcelo Ehrlich; Tomas Kirchhausen; Max L Nibert
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Reovirus polymerase lambda 3 localized by cryo-electron microscopy of virions at a resolution of 7.6 A.

Authors:  Xing Zhang; Stephen B Walker; Paul R Chipman; Max L Nibert; Timothy S Baker
Journal:  Nat Struct Biol       Date:  2003-11-09

3.  Silencing and complementation of reovirus core protein mu2: functional correlations with mu2-microtubule association and differences between virus- and plasmid-derived mu2.

Authors:  John Carvalho; Michelle M Arnold; Max L Nibert
Journal:  Virology       Date:  2007-04-23       Impact factor: 3.616

4.  Conformational changes accompany activation of reovirus RNA-dependent RNA transcription.

Authors:  Israel I Mendez; Scott G Weiner; Yi-Min She; Mark Yeager; Kevin M Coombs
Journal:  J Struct Biol       Date:  2008-01-26       Impact factor: 2.867

5.  Requirements for the formation of membrane pores by the reovirus myristoylated micro1N peptide.

Authors:  Lan Zhang; Melina A Agosto; Tijana Ivanovic; David S King; Max L Nibert; Stephen C Harrison
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

6.  Characterization of an ATPase activity in reovirus cores and its genetic association with core-shell protein lambda1.

Authors:  S Noble; M L Nibert
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

7.  The reovirus mutant tsA279 L2 gene is associated with generation of a spikeless core particle: implications for capsid assembly.

Authors:  P R Hazelton; K M Coombs
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Identification and characterization of a double-stranded RNA- reovirus temperature-sensitive mutant defective in minor core protein mu2.

Authors:  K M Coombs
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

9.  Localization of a C-terminal region of lambda2 protein in reovirus cores.

Authors:  C L Luongo; K A Dryden; D L Farsetta; R L Margraf; T F Severson; N H Olson; B N Fields; T S Baker; M L Nibert
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

10.  Multiple viral core proteins are determinants of reovirus-induced acute myocarditis.

Authors:  B Sherry; M A Blum
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.